Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
1.29
+0.01 (1.12%)
Real-time:   2:17PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.24 - 1.30
52 week 1.24 - 19.32
Open 1.25
Vol / Avg. 106,189.00/428,709.00
Mkt cap 10.81M
P/E     -
Div/yield     -
EPS -8.37
Shares 8.35M
Beta 1.06
Inst. own 7%
Aug 15, 2017
Q2 2017 Celsion Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -3911.90% -4410.75%
Operating margin -3890.38% -4272.13%
EBITD margin - -3924.27%
Return on average assets -64.89% -55.22%
Return on average equity -329.29% -162.69%
Employees 19 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Officers and directors

Jeffrey Wayne Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Donald Braun Ph.D. Independent Director
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters